Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer

M. Kawasaki, Y. Nakanishi, K. Kuwano, K. Takayama, C. Kiyohara, N. Hara

研究成果: ジャーナルへの寄稿記事

51 引用 (Scopus)

抄録

While resistance to chemotherapy is a major problem in lung cancer treatment, there is no useful predictor of treatment response. We thus designed this study to determine the utility of p53 and P-glycoprotein expression in predicting the response to chemotherapy in patients with primary lung cancer, retrospectively. We evaluated transbronchial biopsy (TBB) specimens from 60 patients with lung cancer, who were previously untreated. Formalin-fixed, paraffin-embedded TBB specimens were immunostained using anti-p53 antibody (DO-1) and anti-P-glycoprotein antibody (JSB-1). The positivity of p53 was 63%, and that of P-glycoprotein was 17%. No correlation was observed between p53 and P-glycoprotein immunostaining. Positivity of p53 correlated significantly (P=0.004) with a lack of response to chemotherapy in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC). In contrast, positivity of P-glycoprotein was correlated with chemotherapy resistance in SCLC (P=0.003), but not in NSCLC. Multiple logistic regression analysis revealed that positive immunostaining for p53 was a significant risk factor for chemotherapy resistance in NSCLC. These results suggest that immunostaining of p53 and P-glycoprotein for TBB specimens may help to predict response to chemotherapy in NSCLC and SCLC, although the results should be confirmed in a larger, more homogeneous series.

元の言語英語
ページ(範囲)1352-1357
ページ数6
ジャーナルEuropean Journal of Cancer
34
発行部数9
DOI
出版物ステータス出版済み - 8 1 1998

Fingerprint

P-Glycoprotein
Lung Neoplasms
Drug Therapy
Non-Small Cell Lung Carcinoma
Small Cell Lung Carcinoma
Biopsy
Paraffin
Formaldehyde
Anti-Idiotypic Antibodies
Logistic Models
Regression Analysis
Antibodies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. / Kawasaki, M.; Nakanishi, Y.; Kuwano, K.; Takayama, K.; Kiyohara, C.; Hara, N.

:: European Journal of Cancer, 巻 34, 番号 9, 01.08.1998, p. 1352-1357.

研究成果: ジャーナルへの寄稿記事

Kawasaki, M. ; Nakanishi, Y. ; Kuwano, K. ; Takayama, K. ; Kiyohara, C. ; Hara, N. / Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. :: European Journal of Cancer. 1998 ; 巻 34, 番号 9. pp. 1352-1357.
@article{c8706341e8354212acc920dac7d6a8cc,
title = "Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer",
abstract = "While resistance to chemotherapy is a major problem in lung cancer treatment, there is no useful predictor of treatment response. We thus designed this study to determine the utility of p53 and P-glycoprotein expression in predicting the response to chemotherapy in patients with primary lung cancer, retrospectively. We evaluated transbronchial biopsy (TBB) specimens from 60 patients with lung cancer, who were previously untreated. Formalin-fixed, paraffin-embedded TBB specimens were immunostained using anti-p53 antibody (DO-1) and anti-P-glycoprotein antibody (JSB-1). The positivity of p53 was 63{\%}, and that of P-glycoprotein was 17{\%}. No correlation was observed between p53 and P-glycoprotein immunostaining. Positivity of p53 correlated significantly (P=0.004) with a lack of response to chemotherapy in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC). In contrast, positivity of P-glycoprotein was correlated with chemotherapy resistance in SCLC (P=0.003), but not in NSCLC. Multiple logistic regression analysis revealed that positive immunostaining for p53 was a significant risk factor for chemotherapy resistance in NSCLC. These results suggest that immunostaining of p53 and P-glycoprotein for TBB specimens may help to predict response to chemotherapy in NSCLC and SCLC, although the results should be confirmed in a larger, more homogeneous series.",
author = "M. Kawasaki and Y. Nakanishi and K. Kuwano and K. Takayama and C. Kiyohara and N. Hara",
year = "1998",
month = "8",
day = "1",
doi = "10.1016/S0959-8049(98)00067-7",
language = "English",
volume = "34",
pages = "1352--1357",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer

AU - Kawasaki, M.

AU - Nakanishi, Y.

AU - Kuwano, K.

AU - Takayama, K.

AU - Kiyohara, C.

AU - Hara, N.

PY - 1998/8/1

Y1 - 1998/8/1

N2 - While resistance to chemotherapy is a major problem in lung cancer treatment, there is no useful predictor of treatment response. We thus designed this study to determine the utility of p53 and P-glycoprotein expression in predicting the response to chemotherapy in patients with primary lung cancer, retrospectively. We evaluated transbronchial biopsy (TBB) specimens from 60 patients with lung cancer, who were previously untreated. Formalin-fixed, paraffin-embedded TBB specimens were immunostained using anti-p53 antibody (DO-1) and anti-P-glycoprotein antibody (JSB-1). The positivity of p53 was 63%, and that of P-glycoprotein was 17%. No correlation was observed between p53 and P-glycoprotein immunostaining. Positivity of p53 correlated significantly (P=0.004) with a lack of response to chemotherapy in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC). In contrast, positivity of P-glycoprotein was correlated with chemotherapy resistance in SCLC (P=0.003), but not in NSCLC. Multiple logistic regression analysis revealed that positive immunostaining for p53 was a significant risk factor for chemotherapy resistance in NSCLC. These results suggest that immunostaining of p53 and P-glycoprotein for TBB specimens may help to predict response to chemotherapy in NSCLC and SCLC, although the results should be confirmed in a larger, more homogeneous series.

AB - While resistance to chemotherapy is a major problem in lung cancer treatment, there is no useful predictor of treatment response. We thus designed this study to determine the utility of p53 and P-glycoprotein expression in predicting the response to chemotherapy in patients with primary lung cancer, retrospectively. We evaluated transbronchial biopsy (TBB) specimens from 60 patients with lung cancer, who were previously untreated. Formalin-fixed, paraffin-embedded TBB specimens were immunostained using anti-p53 antibody (DO-1) and anti-P-glycoprotein antibody (JSB-1). The positivity of p53 was 63%, and that of P-glycoprotein was 17%. No correlation was observed between p53 and P-glycoprotein immunostaining. Positivity of p53 correlated significantly (P=0.004) with a lack of response to chemotherapy in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC). In contrast, positivity of P-glycoprotein was correlated with chemotherapy resistance in SCLC (P=0.003), but not in NSCLC. Multiple logistic regression analysis revealed that positive immunostaining for p53 was a significant risk factor for chemotherapy resistance in NSCLC. These results suggest that immunostaining of p53 and P-glycoprotein for TBB specimens may help to predict response to chemotherapy in NSCLC and SCLC, although the results should be confirmed in a larger, more homogeneous series.

UR - http://www.scopus.com/inward/record.url?scp=0032145439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032145439&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(98)00067-7

DO - 10.1016/S0959-8049(98)00067-7

M3 - Article

C2 - 9849416

AN - SCOPUS:0032145439

VL - 34

SP - 1352

EP - 1357

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0959-8049

IS - 9

ER -